switzerland’s pharmaceutical industry is bracing for potential disruption as the United States implements new drug pricing policies set to take effect this year. The changes, which will use international price comparisons-including Switzerland-to negotiate lower drug costs, have raised concerns about the future of pharmaceutical investment and supply within the country. Industry leaders warn the new system could incentivize companies to prioritize other markets, perhaps leading to medication shortages and economic repercussions for Switzerland’s vital healthcare sector.
The pharmaceutical industry faces a critical year as it responds to new U.S. drug pricing policies. A leading industry association has warned of potentially significant economic repercussions if Switzerland fails to adapt to the new system, which uses select countries – including Switzerland – as price reference points.
Click to open the share function.
Industry Concerns Over Potential Supply Disruptions: The U.S. is implementing a new drug pricing system that uses several countries, including Switzerland, as benchmarks. The lowest price in these reference countries will be used as a basis for negotiation. This could reduce revenue for pharmaceutical companies, potentially making it more profitable to avoid supplying the Swiss market altogether. The result could be medication shortages in Switzerland, with significant economic and potentially life-threatening consequences for patients. To prevent this, Switzerland’s regulations regarding drug pricing would need to be revised.
Calls for Comprehensive Reform: The industry is calling for broad reforms and a comprehensive strategy to support Switzerland’s pharmaceutical sector. Health policy and economic competitiveness are increasingly intertwined, and policymakers need to move beyond a siloed approach focused solely on the cost of medications within the basic health insurance system. A supportive environment for research and development is also crucial. Industry leaders believe the time is right for a dedicated pharmaceutical strategy, a proposal that has already gained traction in the Swiss Council of States and is now awaiting debate in the National Council. The goal is to ensure that companies continue to invest and maintain a presence in Switzerland.
The Roche towers in Basel at dusk. Novartis, Roche, and other major corporations are now integral pillars of the Swiss industry. However, the industry warns against complacency.
Keystone / GEORGIOS KEFALAS
Industry Tactics Questioned: Critics argue that warnings of potential drug shortages are intended to bolster the pharmaceutical industry’s position. Preventing shortages would require pricing that is attractive to pharmaceutical companies. While these arguments are strategically sound and relevant to the political process, some consider them overstated. Tobias Müller, a health economist at the Bern University of Applied Sciences, currently sees no urgent need for action regarding availability or price increases. Prices for newly approved drugs are already high, and companies benefit from patent protection for new products. “There is still a strong economic incentive to sell medications in Switzerland, despite the small market,” he says. However, the industry association emphasizes that these concerns are primarily focused on the future, as they would affect newly researched and approved medications.
Click to open the share function.
